Imugene Ltd. | Balance Sheet

Fiscal year is July-June. All values AUD Thousands.
2014
2015
2016
2017
2018
Cash & Short Term Investments
1,222.90
1,957.00
1,582.60
4,814.20
7,822.10
Total Accounts Receivable
524.10
541.40
1,312.60
1,219.60
1,914.70
Other Current Assets
10.70
16.60
17.90
20.50
96.20
Total Current Assets
1,757.60
2,515.00
2,913.10
6,054.30
9,833.00
Net Property, Plant & Equipment
-
-
3.00
3.20
3.90
Total Investments and Advances
-
-
20.00
20.30
20.30
Intangible Assets
6,873.80
6,599.80
6,599.80
6,599.80
7,057.10
Total Assets
8,631.50
9,114.70
9,535.80
12,677.60
16,914.30
ST Debt & Current Portion LT Debt
-
66.70
-
-
-
Accounts Payable
154.90
97.70
265.40
16.20
288.50
Other Current Liabilities
542.10
233.00
428.40
281.30
149.70
Total Current Liabilities
697.00
397.30
693.80
297.50
438.20
Long-Term Debt
-
985.50
-
-
-
Provision for Risks & Charges
-
-
-
-
15.10
Other Liabilities
1,202.20
-
985.50
985.50
985.50
Total Liabilities
1,899.20
1,382.70
1,679.30
1,282.90
1,438.80
Common Equity (Total)
6,732.20
7,732.00
7,856.50
11,394.60
15,475.50
Total Shareholders' Equity
6,732.20
7,732.00
7,856.50
11,394.60
15,475.50
Total Equity
6,732.20
7,732.00
7,856.50
11,394.60
15,475.50
Liabilities & Shareholders' Equity
8,631.50
9,114.70
9,535.80
12,677.60
16,914.30

About Imugene

View Profile
Address
62 Lygon Street
Carlton Victoria (VIC) 3053
Australia
Employees -
Website http://www.imugene.com
Updated 07/08/2019
Imugene Ltd. is a biopharmaceutical company, which engages in the research, development, and commercialisation of health technologies against cancer. Its products include b-cell peptide cancer vaccines, arginine modulators, and mimotopes. The company was founded on May 30, 1986 and is headquartered in Carlton, Australia.